You have free access to this content

Cancer

Cover image for Cancer

15 March 2003

Volume 97, Issue 6

Pages 1369–1590

  1. Original Articles

    1. Top of page
    2. Original Articles
    3. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      Factors influencing arm and axillary symptoms after treatment for node negative breast carcinoma (pages 1369–1375)

      Karen P. L. Yap, David R. McCready, Steven Narod, Lee A. Manchul, Maureen Trudeau and Anthony Fyles

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11218

      • original image
      • original image
      • original image
      • original image

      The factors that contribute to post-operative arm symptoms following breast conserving surgery were examined in a cohort of node-negative breast carcinoma patients within a randomized clinical trial. Older patients and those who did not recieve axillary dissection or breast radiation experienced fewer arm symptoms.

    2. You have free access to this content
      Flow cytometry and quantitative immunohistochemical study of cell cycle regulation proteins in invasive breast carcinoma : Prognostic significance (pages 1376–1386)

      Jean-Jacques Michels, Françoise Duigou, Jacques Marnay, Michel Henry-Amar, Thierry Delozier, Yves Denoux and Jacques Chasle

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11209

      • original image
      • original image
      • original image
      • original image

      Immunohistochemical quantification of p21 combined with S-phase and cyclin A is an important factor for indicating metastasis free survival and overall survival after stratification by treatment in patients with invasive types of breast carcinoma.

    3. You have free access to this content
      Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden (pages 1387–1392)

      Håkan L. Olsson, Christian Ingvar and Anna Bladström

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11205

      Longer use of hormone replacement therapy containing progestins significantly elevates breast carcinoma risk whereas estradiol use does not. Continued use of progestins rendered the highest risks. The yearly risk of breast carcinoma for long-term users of progestins is of the magnitude of 50% the risk of a BRCA1 mutation carrier.

    4. You have free access to this content
      Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women (pages 1393–1403)

      Neesha A. Rodrigues, Deborah Dillon, Darryl Carter, Nicole Parisot and Bruce G. Haffty

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11204

      Several molecular markers in ductal carcinoma in situ (DCIS) were compared between younger and older patients. Younger patients with DCIS more frequently were found to overexpress HER-2/neu.

    5. You have free access to this content
      Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma (pages 1404–1411)

      Lydia B. Zablotska and Alfred I. Neugut

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11214

      Previous studies have reported that women who receive adjuvant radiation therapy (RT) after mastectomy for breast carcinoma have an increased risk of developing a second primary lung carcinoma after 10 years. However, to the authors' knowledge, the risk associated with adjuvant RT after breast-conserving surgery (lumpectomy) has yet to be determined. The current study was performed to confirm and extend earlier findings of the effects of postmastectomy RT on second primary lung carcinoma, and to investigate the impact of postlumpectomy RT on second primary lung carcinoma in the same population and compare the results.

    6. Gastrointestinal Tract
      You have free access to this content
      Combination of tumor necrosis factor-α with sulindac augments its apoptotic potential and suppresses tumor growth of human carcinoma cells in nude mice (pages 1412–1420)

      Hiroshi Yasui, Masaaki Adachi and Kohzoh Imai

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11210

      • original image
      • original image
      • original image
      • original image

      Combination therapy of tumor necrosis factor-alpha (TNF-α) and sulindac may sensitize cancer cells to TNF-α and augment its proapoptotic potential. Therefore, in combination with sulindac,TNF-α may become a potentially useful anticancer agent to suppress tumor growth in a wide range of carcinomas.

    7. You have free access to this content
      Frequency of loss of hMLH1 expression in colorectal carcinoma increases with advancing age (pages 1421–1427)

      Sanjay Kakar, Lawrence J. Burgart, Stephen N. Thibodeau, Kari G. Rabe, Gloria M. Petersen, Richard M. Goldberg and Noralane M. Lindor

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11206

      • original image
      • original image

      Loss of hMLH1 expression in patients with colorectal carcinoma is associated significantly with increasing age, is more pronounced in females, and is more common in tumors that originate in the right colon. A similar but less striking association is observed in males and in tumors that originate in the left colon.

    8. Genitourinary Tract
      You have free access to this content
      Use of quality indicators to evaluate the care of patients with localized prostate carcinoma (pages 1428–1435)

      David C. Miller, Mark S. Litwin, Martin G. Sanda, James E. Montie, Rodney L. Dunn, Jennifer Resh, Howard Sandler and John T. Wei

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11216

      • original image

      The authors demonstrate the feasibility of utilizing the RAND quality indicators to characterize changes in the care of patients with localized prostate carcinoma. Their findings support the use of these quality indicators to measure and potentially improve patient care.

    9. You have free access to this content
      Therapy and outcome of small cell carcinoma of the kidney : Report of two cases and a systematic review of the literature (pages 1436–1441)

      Navneet S. Majhail, Paul Elson and Ronald M. Bukowski

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11199

      • original image
      • original image

      Primary small cell carcinoma originating from the kidneys is an extremely rare neoplasm with poor survival. The use of platinum-based chemotherapy may lead to an improved outcome in this otherwise aggressive tumor.

    10. You have free access to this content
      A Phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma (pages 1442–1446)

      Aminah Jatoi, Neil Ellison, Patrick A. Burch, Jeff A. Sloan, Shaker R. Dakhil, Paul Novotny, Winston Tan, Tom R. Fitch, Kendrith M. Rowland, Charles Y. F. Young and Patrick J. Flynn

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11200

      • original image

      The authors conducted a Phase II trial to explore the antineoplastic effects of green tea in patients with androgen independent prostate carcinoma. Green tea had limited antineoplastic activity, as defined by a decline in prostate specific antigen levels, in the patient population studied.

    11. You have free access to this content
      Down-regulation of fragile histidine triad expression in prostate carcinoma (pages 1447–1452)

      Rebecca L. Fouts, George E. Sandusky, Shaobo Zhang, George J. Eckert, Michael O. Koch, Thomas M. Ulbright, John N. Eble and Liang Cheng

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11201

      • original image

      Using an immunohistochemical method, the authors demonstrated a significant reduction in both the percent of cells stained with the fragile histidine triad (FHIT) antibody and the intensity of FHIT antibody staining in human prostate tumor cells compared with normal prostate cells. Taken together, these data suggest that loss of FHIT expression may be implicated in prostatic carcinogenesis, and FHIT may be a potential target for future therapeutic intervention.

    12. Head and Neck Disease
      You have free access to this content
      Prognostic index for patients with parotid carcinoma : External validation using the nationwide 1985–1994 Dutch Head and Neck Oncology Cooperative Group database (pages 1453–1463)

      Vincent L. M. Vander Poorten, Augustinus A. M. Hart, Bernardus F. A. M. van der Laan, Robert J. Baatenburg de Jong, Johannes J. Manni, Henri A. M. Marres, Cees A. Meeuwis, Herman Lubsen, Chris H. J. Terhaard and Alfonsus J. M. Balm

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11254

      • original image
      • original image

      The prognostic indices for the recurrence-free interval of patients with parotid carcinoma, developed using the patients of The Netherlands Cancer Institute, are validated in the database of the Dutch Head and Neck Oncology Cooperative Group. This validation increases confidence in their generalizability and in their justified prospective use.

    13. You have free access to this content
      Extent of extracapsular spread : A critical prognosticator in oral tongue cancer (pages 1464–1470)

      Jayson S. Greenberg, Robert Fowler, Jose Gomez, Vivian Mo, Dianna Roberts, Adel K. El Naggar and Jeffrey N. Myers

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11202

      • original image
      • original image
      • original image
      • original image
      • original image

      Patients treated for squamous cell carcinoma of the oral tongue with multiple lymph nodes that have extracapsular spread have a far worse prognosis compared with patients with a single lymph node with extracapsular spread. These high-risk patients should be considered for clinical trials that intensify regional and systemic adjuvant therapy.

    14. Hematologic Malignancies
      You have free access to this content
      Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine : Cancer and Leukemia Group B Study 9311 (pages 1471–1480)

      Ted P. Szatrowski, Richard K. Dodge, Carol Reynolds, Carol A. Westbrook, Stanley R. Frankel, Jeffrey Sklar, Carleton C. Stewart, David D. Hurd, Jonathan E. Kolitz, Enrique Velez-Garcia, Richard M. Stone, Clara D. Bloomfield, Charles A. Schiffer and Richard A. Larson

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11219

      • original image
      • original image
      • original image

      Adults with acute lymphoblastic leukemia (ALL) in first remission received lineage specific consolidation therapy either with anti-B4-blocked ricin or with high-dose cytarabine and were monitored by molecular assays for changes in minimal residual disease. Although it was tolerated well, there was little clinical evidence for benefit from anti-B4-blocked ricin.

    15. You have free access to this content
      Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes (pages 1481–1487)

      Apostolia Tsimberidou, Elihu Estey, Jorge Cortes, Deborah Thomas, Stefan Faderl, Srdan Verstovsek, Guillermo Garcia-Manero, Michael Keating, Maher Albitar, Susan O'Brien, Hagop Kantarjian and Francis Giles

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11239

      • original image
      • original image

      A regimen combining gemtuzumab, fludarabine, cytarabine, and cyclosporine achieved a 47% complete remission rate in 59 patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndromes. Grade 3 or 4 toxicities included sepsis (38%), hyperbilirubinemia (31%), hepatic transaminitis (7%). Four patients (7%) developed hepatic venoocclusive disease.

    16. Melanoma
      You have free access to this content
      Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma : An analysis of 3661 patients from a single center (pages 1488–1498)

      Manuela F. Azzola, Helen M. Shaw, John F. Thompson, Seng-jaw Soong, Richard A. Scolyer, Geoffrey F. Watson, Marjorie H. Colman and Yuting Zhang

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11196

      • original image
      • original image
      • original image
      • original image
      • original image

      Tumor mitotic rate was a highly significant independent prognostic variable in 3661 patients with primary melanoma from the Sydney Melanoma Unit, Australia. After tumor thickness, tumor mitotic rate was found to be the second most powerful predictor of survival.

    17. Discipline

      Epidemiology
      You have free access to this content
      Barriers to the participation of African-American patients with cancer in clinical trials : A pilot study (pages 1499–1506)

      Anjali S. Advani, Benjamin Atkeson, Carrie L. Brown, Bercedis L. Peterson, Laura Fish, Jeffrey L. Johnson, Jon P. Gockerman and Marc Gautier

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11213

      Thirty-one percent of African-American oncology patients, compared with 45% of white patients, were willing to participate in a clinical trial (P = 0.05). Barriers to African-American participation included education and income; therefore, intervening in these areas may help increase accrual of African-American patients with cancer onto clinical trials.

    18. You have free access to this content
      Trends in prostate cancer mortality among black men and white men in the United States (pages 1507–1516)

      Kenneth C. Chu, Robert E. Tarone and Harold P. Freeman

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11212

      • original image
      • original image
      • original image
      • original image

      The authors investigated possible machanism for declining prostate cancer mortality rates in the United Staes. Similar incidence, survival, and mortality rate patterns were seen in black men and white men. Increased detection of prostate specific antigen testing after 1986, may explain much of hte recent mortality decrease in both white men and black men.

    19. You have free access to this content
      Health care disparities in older patients with breast carcinoma : Informational support from physicians (pages 1517–1527)

      Rose C. Maly, Barbara Leake and Rebecca A. Silliman

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11211

      The authors documented how physicians provide informational support to patients at the time of a new diagnosis of breast carcinoma and assessed differences in terms of patient age and ethnic group. They found that the provision of information may be optimized by delivering information that is pertinent in terms of age and/or ethnic group, possibly reducing disparities in the treatment of patients with breast carcinoma in vulnerable populations.

    20. You have free access to this content
      Progress in cancer screening practices in the United States : Results from the 2000 National Health Interview Survey (pages 1528–1540)

      Judith Swan, Nancy Breen, Ralph J. Coates, Barbara K. Rimer and Nancy C. Lee

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11208

      • original image

      This article examines the prevalence of cancer screening use in the year 2000 among United States adults and changes since 1987, focusing on differences among subgroups that historically have been underserved. In addition, the authors examine trends among those groups from 1987 through 2000 to determine whether differences in screening prevalence are increasing, staying the same, or decreasing.

    21. Medical Oncology
      You have free access to this content
      Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors (pages 1541–1550)

      Linda S. Elting, Scott B. Cantor, Charles G. Martin, Lois Hamblin, Danna Kurtin, Edgardo Rivera, Saroj Vadhan-Raj and Robert S. Benjamin

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11195

      • original image
      • original image
      • original image

      Thrombocytopenia is a common complication of chemotherapy among patients with solid tumors, but it contributes significantly to the total cost of care in only 40% of cycles in this population. Targeting interventions at high-cost cycles may have significant financial impact.

    22. Pathology
      You have free access to this content
      Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine (pages 1551–1557)

      Maria Planck, Kajsa Ericson, Zofia Piotrowska, Britta Halvarsson, Eva Rambech and Mef Nilbert

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11197

      • original image
      • original image

      Microsatellite instability and immunohistochemical expression of MLH1 and MLH2 was assessed in adenocarcinomas of the small intestine, including a population-based series of 89 tumors and 43 tumors from patients younger than 60 years. Defective MMR was found in 18% of cancers of the small intestine and in 23% of the tumors from the young patients. The frequency of defective MMR in the small intestine thus equals that in colorectal cancer.

    23. You have free access to this content
      The presence of human papillomavirus type 16/18 DNA in blood circulation may act as a risk marker of lung cancer in Taiwan (pages 1558–1563)

      Hui-Ling Chiou, Ming-Fang Wu, Yu-Ching Liaw, Ya-Wen Cheng, Ruey-Hong Wong, Chin-Yi Chen and Huei Lee

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11191

      • original image

      The prevalence of human papillomavirus (HPV) 16/18 DNA was found to be significantly higher in the blood circulation of lung cancer patients versus controls. HPV DNA may serve as a risk marker for lung cancer, which is the leading cause of cancer death in Taiwan.

    24. Psychological Oncology
      You have free access to this content
      Fatigue in ovarian carcinoma patients : A neglected issue? (pages 1564–1572)

      Bernhard Holzner, Georg Kemmler, Verena Meraner, Andrea Maislinger, Martin Kopp, Thomas Bodner, Dominic Nguyen-Van-Tam, Alain G. Zeimet, W. Wolfgang Fleischhacker and Barbara Sperner-Unterweger

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11253

      A remarkably high proportion of ovarian carcinoma survivors suffer from fatigue and other clinical and psychosocial variables, which affect their quality of life. Because this symptom is a key predictor of quality of life, it should be given more attention in aftercare programs.

    25. Translational Research
      You have free access to this content
      Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast carcinoma (pages 1573–1581)

      Reinhard Bos, Petra van der Groep, Astrid E. Greijer, Avi Shvarts, Sybren Meijer, Herbert M. Pinedo, Gregg L. Semenza, Paul J. van Diest and Elsken van der Wall

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11246

      • original image
      • original image
      • original image

      High levels of hypoxia-inducible factor-1α are correlated with protein overexpression and gene amplification of HER-2/neu, and independently predict poor prognosis in patients with lymph node negative breast carcinoma.

    26. You have free access to this content
      Low molecular weight inhibitors of matrix metalloproteinases can enhance the expression of matrix metalloproteinase-2 (gelatinase A) without inhibiting its activation (pages 1582–1588)

      Erika H. M. Kerkvliet, Ineke D. C. Jansen, Ton A. M. Schoenmaker, Andy J. P. Docherty, Wollter Beertsen and Vincent Everts

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11193

      • original image
      • original image
      • original image

      Synthetic low molecular weight inhibitors of matrix metalloproteinases (MMPs) increase (at low concentrations) or decrease (at high concentrations) the expression and activity of MMP-2. These findings provide clues regarding the differing effects such inhibitors appear to have when applied in vivo.

  2. Correspondence

    1. Top of page
    2. Original Articles
    3. Correspondence
    1. You have free access to this content
    2. You have free access to this content
      Author reply (page 1590)

      Dong M. Shin

      Version of Record online: 3 MAR 2003 | DOI: 10.1002/cncr.11215

SEARCH

SEARCH BY CITATION